Literature DB >> 18541118

Bevacizumab in recurrent malignant glioma.

Lauren E Abrey.   

Abstract

Entities:  

Year:  2008        PMID： 18541118     DOI： 10.1007/s11910-008-0035-9

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


× No keyword cloud information.
  4 in total

1.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Authors:  Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

2.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

3.  Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.

Authors:  Wei Chen; Sibylle Delaloye; Daniel H S Silverman; Cheri Geist; Johannes Czernin; James Sayre; Nagichettiar Satyamurthy; Whitney Pope; Albert Lai; Michael E Phelps; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

4.  Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.

Authors:  Ruud P M Dings; Melissa Loren; Hanke Heun; Elizabeth McNiel; Arjan W Griffioen; Kevin H Mayo; Robert J Griffin
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531
  4 in total
  2 in total

1.  Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival.

Authors:  Jan-Karl Burkhardt; Howard Riina; Benjamin J Shin; Paul Christos; Kartik Kesavabhotla; Christoph P Hofstetter; Apostolos John Tsiouris; John A Boockvar
Journal:  World Neurosurg       Date:  2011-11-21       Impact factor: 2.104

2.  Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.

Authors:  John A Boockvar; Apostolos J Tsiouris; Christoph P Hofstetter; Ilhami Kovanlikaya; Sherese Fralin; Kartik Kesavabhotla; Stephen M Seedial; Susan C Pannullo; Theodore H Schwartz; Philip Stieg; Robert D Zimmerman; Jared Knopman; Ronald J Scheff; Paul Christos; Shankar Vallabhajosula; Howard A Riina
Journal:  J Neurosurg       Date:  2010-10-22       Impact factor: 5.115
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.